Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.

Suppr

超能文献

作者信息

Ueda T, Matsuyama S, Yamauchi T, Kishi S, Fukushima T, Tsutani H, Nakamura T, Gotoh N, Masada M

机构信息

First Department of Internal Medicine, Fukui Medical School, Japan.

出版信息

Adv Exp Med Biol. 1998;431:647-51. doi: 10.1007/978-1-4615-5381-6_125.

DOI:10.1007/978-1-4615-5381-6_125

PMID:9598145

Abstract

摘要

相似文献

Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.

Adv Exp Med Biol. 1998;431:647-51. doi: 10.1007/978-1-4615-5381-6_125.

Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 15;1126-1127:121770. doi: 10.1016/j.jchromb.2019.121770. Epub 2019 Aug 19.

Micellar electrokinetic capillary chromatography quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum.

J Chromatogr B Biomed Sci Appl. 2001 Apr 15;754(1):185-92. doi: 10.1016/s0378-4347(00)00605-8.

Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.

Cancer Chemother Pharmacol. 2011 Apr;67(4):765-8. doi: 10.1007/s00280-010-1373-2. Epub 2010 Jun 8.

[Ara-C].

Nihon Rinsho. 2015 Feb;73 Suppl 2:623-7.

Simultaneous determination of 1-β-d-Arabinofuranosylcytosine and two metabolites, 1-β-d-Arabinofuranosyluracil and 1-β-d-Arabinofuranosylcytosine triphosphate in leukemic cell by HPLC-MS/MS and the application to cell pharmacokinetics.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 1;962:14-19. doi: 10.1016/j.jchromb.2014.05.003. Epub 2014 May 14.

Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.

Cancer Chemother Pharmacol. 2000;46(5):382-6. doi: 10.1007/s002800000173.

Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.

Cancer Res. 1991 Aug 15;51(16):4141-5.

Clinical pharmacokinetics of cytarabine formulations.

Clin Pharmacokinet. 2002;41(10):705-18. doi: 10.2165/00003088-200241100-00002.

High-performance liquid chromatographic assay for cytosine arabinoside and uracil arabinoside in cerebrospinal fluid and plasma.

J Chromatogr. 1989 Dec 29;497:302-7. doi: 10.1016/0378-4347(89)80033-7.

引用本文的文献

Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.

BMC Pharmacol Toxicol. 2015 May 2;16:12. doi: 10.1186/s40360-015-0012-2.

1-beta-D-arabinofuranosylcytosine is cytotoxic in quiescent normal lymphocytes undergoing DNA excision repair.

Jpn J Cancer Res. 2002 Dec;93(12):1334-41. doi: 10.1111/j.1349-7006.2002.tb01242.x.

Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.

Jpn J Cancer Res. 2001 May;92(5):546-53. doi: 10.1111/j.1349-7006.2001.tb01128.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验